Market
Novo Nordisk to accelerate drug development with Anthropic AI Competition to adopt AI in pharma grows, alongside concerns

Danish drugmaker Novo Nordisk is teaming up with artificial intelligence (AI) company Anthropic to speed up drug development.
According to BioPharma Dive on the 16th (local time), Novo Nordisk said that day it had signed a collaboration agreement with Anthropic to use AI to accelerate drug discovery and development.
The companies did not disclose specific financial terms. They agreed to work together to identify challenges in the drug development process and develop solutions.
Novo Nordisk CEO Mike Doustdar said in a statement, "Our collaboration with Anthropic will significantly accelerate our research and development (R&D) organization."
The first project will involve testing Anthropic's Claude for Science in specific R&D workflows where the companies expect it to have the greatest impact.
Novo Nordisk plans to use Anthropic's most advanced models for software development as well, expanding AI use across the company.
Competition is intensifying in the pharmaceutical industry to use AI to select drug development investments. Bristol Myers Squibb (BMS), Eli Lilly and Roche have said they will work with Nvidia to secure high-performance computing capabilities.
In May, BMS announced a separate agreement with Anthropic to train Claude on its entire body of knowledge. Merck, Takeda and Eli Lilly have also signed AI contracts worth more than $1 billion with Google Cloud and others.
Novo Nordisk announced in April that it would work with OpenAI to integrate AI tools across all stages of its operations, and has now added the Anthropic agreement.
However, using AI in drug development also presents significant challenges. Large language models (LLMs) can make errors, and some experts warn that expectations far exceed actual results.
Novo Nordisk appeared to acknowledge these concerns, saying, "This collaboration was designed around robust data governance and human oversight" and that it "ensures AI is applied responsibly and in accordance with ethical and compliance standards."

Biobook Team
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss